US · Healthcare · Diagnostics & Research
EPS came in at 2.75 against a street estimate of 2.72 — a beat of 1.1%.
Analysts rate IQVIA Holdings Inc a buy (16 buy, 7 hold, 0 sell out of 23) with an average price target of $272.94.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.13% |
| Harris Associates L.P. | 7.40% |
| Vanguard Capital Management, LLC | 6.70% |
| Vanguard Portfolio Management, LLC | 4.60% |
| State Street Corp | 4.54% |
| JPMorgan Chase & Co | 3.29% |
| Artisan Partners Limited Partnership | 3.07% |
| Geode Capital Management, LLC | 2.71% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-28 |
| Results announced · Q3 2026 | 2026-07-28 |
| Material agreement · Q2 2026 | 2026-06-11 |
| Company announcement · Q2 2026 | 2026-06-04 |
| Company announcement · Q2 2026 | 2026-06-03 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-02-27 |
| Annual report FY2025 | 2026-02-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorizes additional $2 billion common stock repurchase IQVIA Holdings Inc. announced on May 7, 2026, that its board of directors authorized an additional $2 billion stock repurchase program. This brings the total remaining authorization under th | 2026-05-07 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for IQVIA Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.